Disputing the ethics of research: The challenge from bioethics and patient activism to the interpretation of the declaration of helsinki in clinical trials

Bioethics

Volumn 27, Issue 5, 2013, Pages 243-250

  Woods, Simon ^a   Mccormack, Pauline ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Activism; Clinical; Ethics; Helsinki; Neuromuscular; Research; Trials

Indexed keywords

ARTICLE; BEHAVIOR; CHILD; CLINICAL TRIAL (TOPIC); COMPASSIONATE USE; CONFLICT; ETHICS; EUROPE; HEALTH SERVICE; HUMAN; INFORMATION DISSEMINATION; MEDICAL ETHICS; MORALITY; NEUROMUSCULAR DISEASE; PATERNALISM; PATIENT ADVOCACY; PATIENT RIGHT; RARE DISEASE; RESEARCH ETHICS; STANDARD;

CHILD; CLINICAL TRIALS AS TOPIC; COMPASSIONATE USE TRIALS; DISSENT AND DISPUTES; ETHICS, RESEARCH; EUROPE; HELSINKI DECLARATION; HUMANS; INFORMATION DISSEMINATION; MORAL OBLIGATIONS; NEUROMUSCULAR DISEASES; PATERNALISM; PATIENT ADVOCACY; PATIENT RIGHTS; POWER (PSYCHOLOGY); RARE DISEASES; VOLUNTARY HEALTH AGENCIES;

EID: 84878115099     PISSN: 02699702     EISSN: 14678519     Source Type: Journal    
DOI: 10.1111/j.1467-8519.2011.01945.x     Document Type: Article

References (64)

1. M. Pohlschmidt & R. Meadowcroft. 2010. Muscle Disease: the impact. Incidence and prevalence of neuromuscular conditions in the UK. London: Muscular Dystrophy Campaign: 15.
2. Incidence in Europe is: for SMA 1:10,000 live births; for DMD 1:3,500 live male births.
3. E. Longo-Araujo de Melo & M.T. Moreno-Valdes. [Evaluation of the Quality of Life of Children with Duchenne's Progressive Muscular Dystrophy]. Rev Neurol 2007; 45: 81-87
4. J. Rahbek et al. Adult Life with Duchenne Muscular Dystrophy (DMD). Observations among an Emerging and Unforeseen Patient Population. Neuromusc Disord 2005; 15: 743-743.
5. J.E. Bothwell et al. Duchenne Muscular Dystrophy - Parental Perceptions. Clin Pediatr 2002; 41: 105-109
6. F. Boyer et al. Factors Relating to Carer Burden for Families of Persons with Muscular Dystrophy. J Rehabil Medi 2006; 38: 309-315
7. B.A. Gagliardi. The Impact of Duchenne Muscular Dystrophy on Families. Orthop Nurs 1991; 10: 41-49
8. B. Natterlund et al. The Illness Experience of Adult Persons with Muscular Dystrophy. Disabil Rehabil 2001; 23: 788-798.
9. Here we are drawing upon a general ethical concept of vulnerability as being open to wounding or harming; however there are more technical uses of the concept in the context of research ethics. A more nuanced account of vulnerability is needed and we are conscious that judging groups as vulnerable per se is one of the presumptions of paternalism in the research context that patient activism is reacting against.
10. Allied Control Council. Trials of War Criminals Before the Nuernberg Military Tribunals Under Control Council Law No. 10 Washington, DC: US Government Printing Office: 181-1821949
11. World Medical Association. World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. Ferney-Voltaire, France: World Medical Association.1964
12. H. Beecher. Ethics of clinical research. New Engl J Med 1966; 274: 1354-1360
13. M.H. Pappworth. 1967. Human Guinea Pigs: Experimentation on Man. London: Routledge & Kegan Paul.
14. C. Levine. Has AIDS Changed the Ethics of Human Subjects Research? J Law Med Ethics 1988; 16: 167-173
15. D. Shalala. Protecting Research Subjects - What Must Be Done. New Engl J Med 2000; 343: 808-810
16. R. Steinbrook. Protecting Research Subjects - The Crisis at Johns Hopkins. New Engl J Med 2002; 346: 716-720.
17. Council for International Organizations of Medical Sciences (CIOMS). . International Ethical Guidelines for Biomedical Research Involving Human Subjects. 3rd edn. Geneva: CIOMS: 632002
18. Council of Europe. Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine. In Oviedo, 4IV1997. Strasbourg: Council of Europe; World Medical Association. 2008. World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. Ferney-Voltaire, France: World Medical Association.1997
19. J. Harris. Scientific Research is a Moral Duty. J Med Ethics 2005; 31: 242-248
20. Harris argues that the vulnerability of the research subject should not be privileged over and above their duty to participate, or indeed over society's interest in research taking place.
21. D. DeBruin. Reflections on Vulnerability. Bioethics Examiner 2001; 5: 1.
22. H. Munn. 2011. A New Pathway for the Governance of Health Research. New Scientist 11 January
23. J. Thompson et al. Health Researchers' Attitudes towards Public Involvement in Health Research. Health Expect 2009; 12: 209-220
24. Department of Health. Governance Arrangements for NHS Research Ethics Committees. London: Dept of Health.2011
25. M. Foucault. 1973. The Birth of the Clinic. New York: Pantheon
26. E. Goffman. 1961. Asylums: Essays on the Social Situation of Mental Patients and Other Inmates. New York: Doubleday
27. T. Parsons. 1951. The social system. New York: Free Press.
28. J. Harris. 1985. The Value of Life. 1st edn. London: Routledge and Keegan Paul
29. I. Illich. 1976. Medical Nemesis: The expropriation of health. New York: Pantheon; R.M. Veatch. 1981. A Theory of Medical Ethics. New York: Basic Books.
30. S. Epstein. The Construction of Lay Expertise - AIDS Activism and the Forging of Credibility in the Reform of Clinical Trials. Sci Technol Hum Values 1995; 20: 408-437
31. R. Hugman. 1994. Ageing and the care of older people in Europe. Basingstoke: Macmillan.
32. N. Rose & C. Novas. 2005. Biological Citizenship. In Global Assemblages: technology, politics and ethics as anthropological problems. A. Ong & S. J. Collier, eds. Oxford: Blackwell: 439-463.
33. AMS.A new pathway for the regulation and governance of health research. London: Academy of Medical Sciences.2011
34. F. Muntoni et al. 149th ENMC International Workshop and 1st TREAT-NMD Workshop on Planning Phase i/ii Clinical Trials using Systemically Delivered Antisense Oligonucleotides in Duchenne Muscular Dystrophy. Neuromuscul Disord 2008; 18: 268-275.
35. H.M. Evans. Should Patients be Allowed to Veto their Participation in Clinical Research? J Med Ethics 2004; 30: 198-203
36. M.G. Hansson & M. Hakama. Ulysses Contracts for the Doctor and for the Patient. Contemp Clin Trials 2010; 31: 202-206
37. J. Harris. Scientific research is a moral duty. J Med Ethics 2005; 31: 242-248
38. J. Harris & S. Holm. Should we Presume Moral Turpitude in our Children? Small Children and Consent to Medical Research. Theor Med Bioeth 2003; 24: 121-129.
39. R. Rhodes. Rethinking Research Ethics. Am J Bioeth 2010; 10: 19-36.
40. S.D. Edwards & M.J. McNamee. Ethical Concerns regarding Guidelines for the Conduct of Clinical Research on Children. J Med Ethics 2005; 31: 351-354.
41. D. Lupton et al. Caveat Emptor or Blissful Ignorance? Patients and the Consumerist Ethos. Soc Sci Med 1991; 33: 559-568.
42. M.A. Rodwin. Patient Accountability and Quality of Care: Lessons from Medical Consumerism and the Patients' Rights, Women's Health and Disability Rights Movements. Am J Law Med 1994; 20
43. S. Ruzek. Transforming Doctor-patient Relationships. J Health Serv Res Policy 2007; 12: 181-182.
44. C. Waldby. Stem Cells, Tissue Cultures and the Production of Biovalue. Health, An Interdisciplinary Journal for the Social Study of Health, Illness and Medicine 2002; 6: 305-323.
45. D. Dickenson. 2008. Body Shopping. Oxford: Oneworld.
46. R. Dresser. Patient Advocates in Research: New Possibilities, New Problems. 11 Wash Univ J Law Policy 2003: 237-248.
47. P. Furlong. 2010. Advocating for Children. In Goldlab Inaugural Symposium. Colorado: Goldlab.
48. V. Rabeharisoa. The Struggle against Neuromuscular Diseases in France and the Emergence of the 'Partnership Model' of Patient Organization. Soc Sci Med 2003; 57: 2127-2136.
49. Genethon. 2011. Homepage.
50. V. Rabeharisoa & M. Callon. The Involvement of Patients' Associations in Research. Int Soc Sci J 2002; 54: 57-65.
51. S. Woods et al. 2011.The therapeutic misconception, decision making and informed consent: the ethics of trial participation for neuromuscular disorders. In preparation.
52. F.G. Miller & S. Joffe. Limits to Research Risks. J Med Ethics 2009; 35: 445-449
53. M.L. Slevin et al. Who Should Measure the Quality of Life, the Doctor or the Patient? Br J Cancer 1988; 57: 109-112.
54. P. McCormack. 2009. Notes from Action Duchenne conference. Personal communication.
55. L. Baker. 2008. The views of young men living with Duchenne Muscular Dystrophy. London: Action Duchenne.
56. A. Aartsma-Rus, et al. The Risks of Therapeutic Misconception and Individual Patient (n = 1) 'Trials' in Rare Diseases such as Duchenne Dystrophy. Neuromuscul Disord 2011; 21.
57. F. Muntoni. 2009. The Development of Antisense Oligonucleotide Therapies for Duchenne Muscular Dystrophy. Report on a TREATNMD meeting hosted by European Medicines Agency, 25 September 2009. TREAT-NMD Network.
58. Patient Partner. 2011. Patient Involvement in Clinical Research. A Guide for Patient Organizations and Patient Representatives. Soest: Patient Partner; Patient Partner. . Patient Involvement in Clinical Research. A Guide for Sponsors and Investigators. Soest: Patient Partner.2011
59. Nature Biotechnology. Gunvalson Decision sends Shockwaves through Industry. Nature Biotechnology 2008; 26: 1201-1201
60. Author. Jacob Gunvalson, Terminally Ill, Can't Demand Experimental Drug: Court. Huffington Post 16 December.2008
61. P.S. Appelbaum et al. The Therapeutic Misconception - Informed Consent in Psychiatric Research. Int J Law Psychiatry 1982; 5: 319-329.
62. In addition, neither of these confusions acknowledge the fact that over 80% of clinical trials are unsuccessful. R. Greville. . Cost and Affordability of Medicines. Blaenau Gwent, Wales: Bevan Foundation.2010
63. R. Abelson. 2008. Advocating a treatment, but Denied Access to It. The New York Times 17 July.
64. The NHS ethics review application form asks for evidence of patient involvement but it is not compulsory to have patient involvement.